Welcome to our dedicated page for OptimizeRx SEC filings (Ticker: OPRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
OptimizeRx Corporation filings document the public-company records of a Nevada healthcare technology issuer serving life sciences companies through HCP and patient engagement platforms. Its SEC disclosures include material-event reports on operating results, financing agreement amendments, share repurchase authorization, executive and board appointments, auditor changes, and related internal-control matters.
OptimizeRx proxy materials cover director elections, advisory executive compensation votes, equity incentive plan amendments, and auditor ratification. The filings also provide formal governance records for board composition, committee service, compensation arrangements, capital-structure actions, and risk-related disclosures tied to the company’s digital healthcare marketing operations.
OptimizeRx Corp (OPRX) reported that Chief Business Officer Andrew J. D'Silva had 1,432 shares of common stock withheld on September 1, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units, treated as a disposition under Section 16, at a value of $7.86 per share. After this withholding, he directly holds 99,660 shares of OptimizeRx common stock, and no Rule 10b5-1 trading plan is reported.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (symbol: OPRX) is the issuer of record for a Form 4 filing submitted to the SEC.
OptimizeRx Corp (OPRX) reported an insider transaction by Chief Operating Officer Brendan W. Merrell. On 2026-08-21, 1,020 shares of common stock were withheld at $7.71 per share to satisfy tax withholding obligations upon the vesting of restricted stock units. This withholding is treated as a disposition under Section 16, and Merrell now holds 25,187 shares of common stock directly.
OptimizeRx Corp (OPRX) reported that Chief Executive Officer Stephen L. Silvestro had 1,737 shares of Common Stock withheld on 2026-08-21 to satisfy his tax withholding obligations upon the vesting of restricted stock units. This Code F transaction is treated as a disposition under Section 16, and Silvestro now holds 183,551 shares of OptimizeRx common stock directly.
OptimizeRx Corp (OPRX) reported that Chief Legal & Admin Officer Marion Odence-Ford had 1,529 shares of common stock withheld on 2026-08-21 to satisfy tax withholding obligations upon vesting of restricted stock units. This withholding is treated as a disposition under Section 16. After this transaction, Odence-Ford directly held 90,407 shares of OptimizeRx common stock.
OptimizeRx Corp (OPRX) reported that Chief Business Officer Andrew J. D'Silva had 1,243 shares of common stock withheld on August 21, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. The withholding, treated as a disposition under Section 16, left him with 43,492 directly held shares.
OptimizeRx Corp (OPRX) reported an insider Form 4 for Edward Stelmakh, Chief Finance & Strat Officer. On 2026-08-21, 1,381 shares of common stock were disposed of under code F at $7.71 per share, representing shares delivered or withheld for payment of exercise price or tax liability. Following this transaction, Stelmakh’s reported direct holdings total 121,791 shares of OptimizeRx common stock. A footnote states that the filing should not be construed as an admission of beneficial ownership or that the filing is legally required.